Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

AIMS: There is a controversy as to the relative efficacy of (177)Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether (177)L...

Descripción completa

Detalles Bibliográficos
Autores principales: von Eyben, Finn Edler, Roviello, Giandomenico, Kiljunen, Timo, Uprimny, Christian, Virgolini, Irene, Kairemo, Kalevi, Joensuu, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787223/
https://www.ncbi.nlm.nih.gov/pubmed/29247284
http://dx.doi.org/10.1007/s00259-017-3895-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787223/
https://www.ncbi.nlm.nih.gov/pubmed/29247284
http://dx.doi.org/10.1007/s00259-017-3895-x

Ejemplares similares